eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2020
vol. 16
 
Share:
Share:
more
 
 
abstract:
Systematic review/Meta-analysis

A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients

Hui Lv
,
Qing-Hua Zhou
,
Dian-Sheng Zhong

Arch Med Sci 2020; 16 (2): 253–259
Online publish date: 2020/03/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The aim of the present study was to assess the efficacy of molecularly targeted agents (MTAs) in the treatment of elderly patients with metastatic oesophago-gastric cancer (mOGC).

Material and methods
We systematically searched electronic databases and abstracts presented at American Society of Clinical Oncology (ASCO) meetings up to January 31, 2017. Hazard ratios (HRs) were used to estimate overall survival (OS) and progression-free survival (PFS). Subgroup analysis and publication bias were also evaluated. All statistical analysis was conducted using Comprehensive Meta Analysis software (Version 2.0).

Results
A total of 2,149 elderly patients with mOGC from thirteen trials were included. Compared to non-MTA-containing regimens, OS was significantly improved in the MTA-containing regimens (HR = 0.86, 95% CI: 0.75–0.99, p = 0.037), but not for PFS (HR = 1.05, 95% CI: 0.85–1.30, p = 0.67). In addition, subgroup analysis indicated that MTA-containing regimens as second-line therapy in elderly mOGC patients significantly improved PFS (HR = 0.58; 95% CI: 0.39–0.85, p = 0.005) and OS (HR = 0.82, 95% CI: 0.70–0.96, p = 0.016), but did not significantly improve PFS (HR = 1.36; 95% CI: 1.06–1.76, p = 0.017) and OS (HR = 0.98, 95% CI: 0.77–1.27, p = 0.90) for MTA-containing regimens as first-line therapy in these patients. No publication bias was detected by Begg’s and Egger’s tests for OS and PFS.

Conclusions
Our results indicate that the MTA-containing therapies significantly improve OS but not for PFS in elderly mOGC patients. Sub-group analysis shows that improved efficacy is only observed in the second-line setting and not in the first-line setting. Our findings support the use of angiogenesis as second-line treatment for elderly mOGC patients.

keywords:

oesophago-gastric cancer, elderly, systematic review, meta-analysis, targeted agents

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe